Tuesday, June 24

Tuesday	, June 24	
<session 1="" room=""></session>		
8:00~9:00	Session 9 Adult Glioma (Sponsor: Ohara Pharmaceutical Co., Ltd.)	
Moderator:	Michael Weller (USA) Patrick Wen (USA)	
O-058	Updated results of Phase 3 STELLAR study showing effornithine improves overall survival (OS) and progression free survival (PFS) in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma Howard Colman (USA)	
O-059	A UNIFIED PHARMACODYNAMIC AND PHARMACOKINETIC ANALYSIS OF PARP-MEDIATED RADIOSENSIZATION IN PATIENTS WITH GLIOBLASTOMA Nader Sanai (USA)	
O-060	PRELIMINARY RESULTS OF A PHASE 1 STUDY OF AUTOLOGOUS ANTI-EGFRVIII SYNNOTCH RECEPTOR INDUCED ANTI-EPHA2/IL-13R α 2 CAR (E-SYNC) T CELLS IN ADULT PARTICIPANTS WITH EGFRVIII+ GLIOBLASTOMA	
O-061	Jennifer L. Clarke (USA) PRIOR VORASIDENIB THERAPY ENHANCES SALVAGE CHEMORADIATION EFFICACY IN A	
	GENETIC MOUSE MODEL OF IDH INHIBITOR RESPONSIVE GLIOMA Samuel K. McBrayer (USA)	
O-062	GENETIC LANDSCAPE IN IDH MUTANT LOWER GRADE GLIOMAS STRATIFIED BY AGE	
0.002	Katherine B. Peters (USA)	
O-063	Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase 2/3 Bayesian Randomized Platform Trial Patrick Wen (USA)	
O-064	A PROSPECTIVE, RANDOMIZED, SINGLE-CENTER TRIAL OF TTF TOGETHER WITH RADIATION THERAPY AND TEMOZOLOMIDE, COMPARED TO TEMOZOLOMIDE AND RADIATION THERAPY, CONTINUED BY TEMOZOLOMIDE AND TTF IN PATIENTS WITH NEWLY DIAGNOSED GBM	
	Rachel Grossman (Israel)	
O-065	EVALUATION OF VAL-083 IN GBM AGILE, A PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA	
	John de Groot (USA)	
O-066	Cellular plasticity leading to treatment resistance in gliomas Chul-Kee Park (Korea)	
O-067	ACCOUNTING FOR HETEROGENEITY IN GLIOBLASTOMA DRUG SCREENING MODELS Sarah Best (Australia)	
O-068	The tumoral molecular landscape of long-term survivors with glioblastoma, isocitrate dehydrogenase wildtype glioblastoma: lessons from ETERNITY (EORTC 1419) Michael Weller (Switzerland)	
9:00~9:30	Special Lecture 3 Immunotherapy	
	(Sponsor: NIHON SERVIER CO., LTD. MEDICAL & PATIENT AFFAIRS)	
Moderator:	Yoshiki Arakawa (Japan)	
SL3	Immuno-genomic analysis elucidates immunosuppressive mechanisms in the tumor microenvironment	
	Hiroyoshi Nishikawa (Japan)	

9:30~9:40

Coffee Break

9:40~11:10	Session 10 Epigenetics and Metabolism (Sponsor: Chimerix, Inc.)
Moderator:	Sabine Mueller (USA)
	Suzanne Baker (USA)
	Hirokazu Takami (Japan)
O-069	EPIGENETIC AND TRANSCRIPTIONAL DEPENDENCIES IN HISTONE MUTANT GLIOMA
	Suzanne J. Baker (USA)
O-070	Perioperative clinical trial reveals decreased synaptic signaling and altered metabolism as consequences of mutant IDH inhibition
	James Richard Whittle (Australia)
O-071	CLINICAL AND MOLECULAR CHARACTERISTICS OF DIFFUSE NON-MIDLINE GLIOMAS WITH H3F3A GENE MUTATION IN THE KANSAI MOLECULAR DIAGNOSIS NETWORK FOR CNS TUMORS (KANSAI NETWORK): MULTICENTER RETROSPECTIVE COHORT STUDY
	Yonehiro Kanemura (Japan)
O-072	LACTYLATION FUELS NUCLEOTIDE BIOSYNTHESIS AND FACILITATES DEUTERIUM METABOLIC IMAGING OF TUMOR PROLIFERATION IN H3K27M-MUTANT GLIOMAS
	Pavithra Viswanath (USA)
O-073	SPATIAL MULTI-MODAL OMICS PROFILING OF THE INFILTRATIVE EDGE IN IDH-MUTATED GLIOMA
	Saskia Freytag (Australia)
O-074	TARGETING EPIGENETIC DRIVERS OF GBM USING AN MRNA-BASED EPIGENOME MEMORY EDITOR
	John Liu (USA)
O-075	Methylation based subclassification of glioblastoma. its clinical utility and biomarker discovery
	Franz Lennard Ricklefs (Germany)
O-076	GENOME-WIDE CHROMATIN DYSFUNCTION ENGAGES LINEAGE-DEFINING CORE REGULATORY CIRCUITS TO DISRUPT DIFFERENTATION IN ATRX-DEFICIENT GLIOMA
O-077	Jason T. Huse (USA)
	The genomic landscape of primary mismatch repair deficient glioma provide insights on tumorigenesis and immunotherapy
	Uri Tabori (Canada)
	TRANSCRIPTION ELONGATION Pintana Marking (Januar)
0.070	Rintaro Hashizume (Japan)
O-079	Targeting Energy Metabolism in Malignant Gliomas and Tumor Microenvironment by NAMPT Inhibition
	Vinay K. Puduvalli (USA)
	Multi-dimensional tumor cell plasticity promotes glioblastoma heterogeneity and therapeutic resistance
	Jeremy N. Rich (USA)
O-081	METABOLIC ADAPTATIONS OF GLIOBLASTOMA DURING TUMOR RELAPSE
	Thomas Daubon (France)
O-082	AP-1 ACTIVATION MEDIATES T CELL DYSFUNCTION IN GLIOBLASTOMA
	Malte Mohme (Germany)
O-083	Clinical effect of ketogenic diet combined with standard therapy including bevacizumab for malignan glioma
	Takashi Sasayama (Japan)

11:10~11:25 Special Lecture 4 PCNSL (Sponsor: ONO PHARMACEUTICAL Co., Ltd.) Yoshitaka Narita (Japan) Moderator: SL4 A SECOND GENERATION BRUTON'S TYROSINE KINASE (BTK) INHIBITOR TIRABRUTINIB IN THE TREATMENT OF PRIMARY CNS LYMPHOMA **Motoo Nagane (Japan)** 11:25~11:45 Session 11 PCNSL Yoshitaka Narita (Japan) Moderator: O-084 TIRABRUTINIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 PROSPECT STUDY Tracy Batchelor (USA) O-085 R-MPV followed by maintenance MPV for newly diagnosed primary CNS lymphoma in elderly patients Kazuhiko Mishima (Japan) O-086 Novel patient-derived xenograft models from Central Nervous Lymphoma patients for translational research Kensuke Tateishi (Japan) 11:55~12:55 Luncheon Seminar 2 Adult Glioma (Sponsor: Novocure K.K.) Moderator: Motoo Nagane (Japan) LS2-1 Phase I/II Study of Maintenance Therapy with Metformin and Temozolomide targeting Cancer Stem Cells for Newly Diagnosed Glioblastoma Yoshitaka Narita (Japan) LS2-2 Cerebral blood flow and histological analysis for the accurate differentiation of infiltrating tumor and vasogenic edema in glioblastoma Yoshiko Okita (Japan) DYNAMIC CHANGES IN DNA HYDROXYMETHYLATION DURING MALIGNANT PROGRESSION OF LS2-3 **IDH-MUTANT GLIOMAS** Akitake Mukasa (Japan) D-ASPARAGINE AS A URINE BIOMARKER FOR GLIOBLASTOMA LS2-4 Mitsutoshi Nakada (Japan) LS2-5 Glutaminolysis is Associated with Mitochondrial Pathway Activation and Can Be Therapeutically Targeted in Glioblastoma Koji Yoshimoto (Japan) LS2-6 Utility of Rapid Molecular Diagnosis in Glioma Surgery Ryuta Saito (Japan)